Biotech Values

[DewDiligence]

Keytruda monotherapy shows statsig superior OS compared to chemo in second-line bladder cancer in phase-3 KEYNOTE-045 study:

http://finance.yahoo.com/news/merck-keynote-045-studying-keytruda-104500768.html

MRK…today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA…in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS). In this trial, KEYTRUDA was superior compared to investigator choice chemotherapy. Based on a pre-specified interim analysis, an independent Data Monitoring Committee has recommended that the trial be stopped early.

This PR contains no actual data; MRK will present the KEYNOTE-045 data at an unspecified medical conference.

Note: KEYNOTE-045 is not the bladder-cancer study MRK presented at ESMO (#msg-125667541). That was a single-arm study of Keytruda monotherapy in which patients were considered too frail to receive chemo.